We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biotech firm BioCryst plans to begin trials soon on an investigational flu drug that could be used against the avian flu virus H5N1 -- a development that comes amid new reports that some patients with avian flu are developing resistance to the current treatment Tamiflu.